)
)
ArriVent BioPharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from ArriVent BioPharma Inc
Access all reports
ArriVent BioPharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of innovative medicines to meet the unmet medical needs of patients with cancers. The company specializes in developing targeted cancer therapies, including for non-small-cell lung cancer (NSCLC) and other solid tumors. A key product in its pipeline is Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
AVBP
Country
🇺🇸 United States